Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
Datopotamab deruxtecan (Dato-DXd) in combination with durvalumab as first-line treatment for unresectable locally advanced or metastatic triple-negative breast cancer: results from arms 7 and 8 of the phase Ib/II BEGONIA study.
Annals of oncology : official journal of the European Society for Medical Oncology·2026
Clinical and molecular biomarkers for prediction of endocrine response after short preoperative endocrine therapy in the WSG ADAPT-HR+/HER2- and ADAPTcycle trials (N = 7914).
Annals of oncology : official journal of the European Society for Medical Oncology·2026
Datopotamab deruxtecan in patients with untreated, advanced triple-negative breast cancer (TROPION-Breast02): a randomised, open-label, international, phase III trial.
Annals of oncology : official journal of the European Society for Medical Oncology·2026
A-BRAVE trial: a phase III randomized trial with anti-PD-L1 avelumab in high-risk triple-negative early breast cancer patients.
Annals of oncology : official journal of the European Society for Medical Oncology·2025
Hierarchical Nanofibrous Membranes With Fluorescent Competitive Absorption and Self-Adaptive Thermal-Wet Regulation for Radiative Cooling.
Small (Weinheim an der Bergstrasse, Germany)·2026
Explantation rates and failure mechanisms in early cannulation grafts: A comparative study between Flixene and Gore Acuseal.
The journal of vascular access·2026
Microfluidic Engineering of Microgels: A Review of Emerging Technologies, Materials, Fabrication Strategies, and Applications.
Advanced healthcare materials·2026
Soft Interactions, Rather Than Crowder Size, Determine Deviations From Arrhenius-Like Kinetics of Phosphofructokinase-1.
Angewandte Chemie (International ed. in English)·2026